Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.

You may also be interested in...



Voyager Lifts Off With $45M From Third Rock Ventures

The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.

BIO 2013 Wednesday Roundup: Roche Partnering, Crowdfunding, Alzheimer’s and Deal Trend Data

Our survey of news and notes from the third day of the BIO 2013 conference includes insights from panel discussions about the environments for licensing deals and Alzheimer’s disease research, an interview with a Roche exec about the company’s partnering strategy, and news about a crowdfunding portal that will connect VCs and companies with accredited individual investors.

Third Rock Continues To Attract Investors, Closes $516M Fund

The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel